{"title":"新药:Faricimab-svoa (Vabysmo™)治疗黄斑变性和糖尿病性黄斑水肿，Omidenepag异丙基(Omlonti™)治疗青光眼和高眼压。","authors":"Lana Gettman","doi":"10.4140/TCP.n.2023.497","DOIUrl":null,"url":null,"abstract":"<p><p>Two drugs are covered in this quarterly column. Faricimab-svoa (Vabysmo<sup>™</sup>) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti<sup>™</sup>) for Glaucoma and Ocular Hypertension.</p>","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"38 12","pages":"497-500"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Drugs: Faricimab-svoa (Vabysmo<sup>™</sup>) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti<sup>™</sup>) for Glaucoma and Ocular Hypertension.\",\"authors\":\"Lana Gettman\",\"doi\":\"10.4140/TCP.n.2023.497\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Two drugs are covered in this quarterly column. Faricimab-svoa (Vabysmo<sup>™</sup>) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti<sup>™</sup>) for Glaucoma and Ocular Hypertension.</p>\",\"PeriodicalId\":41635,\"journal\":{\"name\":\"Senior Care Pharmacist\",\"volume\":\"38 12\",\"pages\":\"497-500\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Senior Care Pharmacist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4140/TCP.n.2023.497\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Senior Care Pharmacist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4140/TCP.n.2023.497","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
New Drugs: Faricimab-svoa (Vabysmo™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti™) for Glaucoma and Ocular Hypertension.
Two drugs are covered in this quarterly column. Faricimab-svoa (Vabysmo™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti™) for Glaucoma and Ocular Hypertension.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
